Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Northwestern University
Northwestern University
Indiana University
Merck Sharp & Dohme LLC
City of Hope Medical Center
Mayo Clinic
University of Chicago
Merck Sharp & Dohme LLC
University of Chicago
Merus B.V.
University of Chicago
Stingthera, Inc.
Mayo Clinic
Sunnybrook Health Sciences Centre
Seagen Inc.
Children's Hospital Medical Center, Cincinnati
Ohio State University Comprehensive Cancer Center